ASH Letter to Senate Finance Committee Regarding Certain Radioimmunotherapy Agents (December 4, 2007)

Sign-on Letter to CMS in Support of Flexibility on PQRI (October 29, 2007)

ASH Letter to CMS Requesting a Reopening of the NCD (October 22, 2007)

ASH Comments to CMS on Expanding Beneficiary Access Under Medicare Part D by Authorizing Additional Compendia (October 17, 2007)

ASH Comments to CMS on the Public Release of Medically Unlikely Edits (MUEs) (September 18, 2007)

ASH Comments to CMS Regarding the Hospital Outpatient Prospective Payment System (September 11, 2007)

Sign-On Letter to Senate Majority Leader Harry Reid Regarding Physician Payment (September 11, 2007)

ASH Comments to NIH on Peer Review Process (September 10, 2007)

Sign-On Letter to Department of Education Regarding Increased Aggregate Combined Stafford Loan Limit for Health Professions Students (September 10, 2007)

ASH Comments to CMS Regarding Physician Fee Schedule Revisions (August 28, 2007)

ASH’s comments on the NCRR Strategic Plan (August 24, 2007)

Proposed Decision Memorandum for Second Reconsideration of the Clinical Trial Policy, Renamed the Clinical Research Policy (CAG-0071R2) (August 16, 2007)

ASH Letter Requesting the Reopening of National Coverage Decision for ESAs for Non-Renal Disease Indications (August 14, 2007)

ASH Letter Regarding National Coverage Decision for ESAs for Non-Renal Disease Indications (August 8, 2007)

ASH-AACR Letter to Centers for Medicare and Medicaid Services Regarding National Coverage Analysis for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N) (July 20, 2007)

ASH Comments to National Institute on Aging (NIA) Strategic Directions for Research on Aging (July 3, 2007)

Sign-On Letter to Centers for Medicare and Medicaid Services Regarding Medicaid Program and Graduate Medical Education (June 26, 2007)

ASH Comments on Medicare Proposed National Coverage Policy on Erythropoiesis-Stimulating Agents (ESAs) (June 13, 2007)

ASH Comments to CMS on Proposed Revisions to the Medicare Clinical Trial Policy (May 9, 2007)

ASH Comments to the FDA Oncologic Drug Advisory Committee Concerning Erythropoiesis Stimulating Agents
(April 25, 2007)

Sign-On Letter Urging the Centers for Medicare and Medicaid Services to Adopt Policy Changes to the 2008 Medicare Payment Schedule (April 20, 2007)

ASH Comments to the Centers for Medicare and Medicaid Services on Coverage for Erythropoiesis Stimulating Agents (ESAs) (April 12, 2007)

ASH Letter to U.S. Senate Regarding Stem Cell Research Enhancement Act (S. 5) (April 4, 2007)

Sign-On Letter to Congress in Support of Increased FY 2008 Funding for Federal Public Health Activities and Programs (February 26, 2007)

Sign-On Letter to Congress Regarding Support of the Stem Cell Research Enhancement Act (January 11, 2007)

ASH Letter to U.S. House of Representatives Regarding the Stem Cell Research Enhancement Act (HR 3)
(January 9, 2007)

NCCR Letter Urging Congress to Pass the Stem Cell Research Enhancement Act of 2007 (January 9, 2007)

Archive

2006 Testimony & Correspondence

2005 Testimony & Correspondence

2004 Testimony & Correspondence

2003 Testimony & Correspondence